Loading...
Retrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failure
Patel, Maulin Gangemi, Andrew Marron, Robert Chowdhury, Junad Yousef, Ibraheem Zheng, Matthew Mills, Nicole Giurintano, Julie
Patel, Maulin
Gangemi, Andrew
Marron, Robert
Chowdhury, Junad
Yousef, Ibraheem
Zheng, Matthew
Mills, Nicole
Giurintano, Julie
Citations
Altmetric:
Genre
Journal article
Date
2020-08-26
Advisor
Committee member
Group
Department
Thoracic Medicine and Surgery
Subject
Permanent link to this record
Collections
Research Projects
Organizational Units
Journal Issue
DOI
http://dx.doi.org/10.1136/bmjresp-2020-000650
Abstract
Invasive mechanical has been associated with high mortality in COVID-19. Alternative therapy of high flow nasal therapy (HFNT) has been greatly debated around the world for use in COVID-19 pandemic due to concern for increased healthcare worker transmission.This was a retrospective analysis of consecutive patients admitted to Temple University Hospital in Philadelphia, Pennsylvania, from 10 March 2020 to 24 April 2020 with moderate-to-severe respiratory failure treated with HFNT. Primary outcome was prevention of intubation. Of the 445 patients with COVID-19, 104 met our inclusion criteria. The average age was 60.66 (+13.50) years, 49 (47.12 %) were female, 53 (50.96%) were African-American, 23 (22.12%) Hispanic. Forty-three patients (43.43%) were smokers. Saturation to fraction ratio and chest X-ray scores had a statistically significant improvement from day 1 to day 7. 67 of 104 (64.42%) were able to avoid invasive mechanical ventilation in our cohort. Incidence of hospital-associated/ventilator-associated pneumonia was 2.9%. Overall, mortality was 14.44% (n=15) in our cohort with 13 (34.4%) in the progressed to intubation group and 2 (2.9%) in the non-intubation group. Mortality and incidence of pneumonia was statistically higher in the progressed to intubation group.
Description
Citation
Patel M, Gangemi A, Marron R, et alRetrospective analysis of high flow nasal therapy in COVID-19-related moderate-to-severe hypoxaemic respiratory failureBMJ Open Respiratory Research 2020;7:e000650. doi: 10.1136/bmjresp-2020-000650
Citation to related work
BMJ
Has part
BMJ Open Respiratory Research, Vol. 7, Issue 1
ADA compliance
For Americans with Disabilities Act (ADA) accommodation, including help with reading this content, please contact scholarshare@temple.edu